A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. Benefit and weak benefit are separate tags. Weak benefit is the tag “Significant, low-quality evidence”. No harm tag ≠ safe. Floors are chosen from efficacy studies. Risks live on the dose page and in the interaction checker. “Not stated in the abstract” means the PubMed abstract we checked did not name a funder. It does not mean the full paper is silent. Copying a card copies the dose-page link, the safety link, and these limits, under CC BY 4.0. The dataset is the same file. The retraction radar, the funding meter, and the enforcement log are the other columns on this desk.
26ingredients
54floors
24benefit
4weak benefit
0harm tags in floors
26uncertain
This is not a success rate. Guides choose which studies become floors. No harm tag ≠ safe. A zero in “harm tags in floors” means no floor was tagged harm. It does not mean the ingredient is safe.
| Ingredient | Benefit | Weak benefit | Harm tags | Uncertain |
|---|---|---|---|---|
| 5-HTP | 1 | 2 | 0 | 0 |
| Ashwagandha | 2 | 0 | 0 | 0 |
| Berberine | 0 | 0 | 0 | 2 |
| Chromium picolinate | 0 | 1 | 0 | 1 |
| Collagen peptides (hydrolyzed) | 2 | 0 | 0 | 0 |
| Creatine monohydrate | 1 | 0 | 0 | 1 |
| Dietary protein (complete) | 1 | 0 | 0 | 1 |
| Garlic (aged extract) | 0 | 1 | 0 | 0 |
| Ginkgo biloba (EGb 761) | 0 | 0 | 0 | 2 |
| Glucomannan (konjac) | 0 | 0 | 0 | 1 |
| Green tea extract (EGCG) | 0 | 0 | 0 | 2 |
| Korean red ginseng (Panax ginseng) | 2 | 0 | 0 | 1 |
| L-arginine | 1 | 0 | 0 | 0 |
| L-citrulline | 1 | 0 | 0 | 0 |
| Maca root (Lepidium meyenii) | 1 | 0 | 0 | 2 |
| Magnesium (elemental) | 2 | 0 | 0 | 2 |
| Magnesium L-threonate | 0 | 0 | 0 | 1 |
| Melatonin | 2 | 0 | 0 | 0 |
| Nicotinamide riboside | 0 | 0 | 0 | 1 |
| Omega-3 (EPA + DHA combined) | 2 | 0 | 0 | 1 |
| Potassium | 0 | 0 | 0 | 1 |
| Psyllium husk fibre | 2 | 0 | 0 | 0 |
| Red yeast rice | 1 | 0 | 0 | 0 |
| Saffron (Crocus sativus) extract | 2 | 0 | 0 | 2 |
| Urolithin A | 0 | 0 | 0 | 4 |
| Vitamin B12 (cobalamin) | 1 | 0 | 0 | 1 |
| Benefit | Antidepressant add-on (300 mg/day)
300 mg/day added to chlorimipramine 50 mg/day in hospitalized depression, double-blind against chlorimipramine plus placebo, for 28 days. Two patients on chlorimipramine plus placebo dropped out. Supervised add-on context only, never a basis for stacking on top of serotonergic medication without a prescriber. |
|---|---|
| Weak benefit | Depression trial in Parkinson's disease (50 mg/day)
50 mg/day for 4 weeks in a randomized double-blind placebo-controlled crossover trial in Parkinson's disease depression; significant HDRS improvement, no effect on apathy, and the authors call it preliminary. A single small trial in one population, cited by our 5-HTP with SSRIs guide. Obesity trial (900 mg/day)
900 mg/day in 20 obese adults randomly assigned to 5-HTP or placebo, across two consecutive double-blind 6-week periods. No diet was prescribed during the first period. A 5040-kJ/d diet was recommended for the second. Significant weight loss, lower carbohydrate intake, and earlier satiety were seen on 5-HTP during both periods. The authors report good tolerance. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | No floor is tagged as missed, secondary-only, or untagged. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
5-HTP Dose page: https://supplementbrief.com/dose/5-htp/ Safety: https://supplementbrief.com/dose/5-htp/#dose-red-flags-heading Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit Antidepressant add-on (300 mg/day) 300 mg · over 28 days · daily · n=26 · limited evidence · Benefit shown · Not stated in the abstract 300 mg/day added to chlorimipramine 50 mg/day in hospitalized depression, double-blind against chlorimipramine plus placebo, for 28 days. Two patients on chlorimipramine plus placebo dropped out. Supervised add-on context only, never a basis for stacking on top of serotonergic medication without a prescriber. PMID 6381336 Weak benefit Depression trial in Parkinson's disease (50 mg/day) 50 mg · over 4 weeks · daily · n=25 · limited evidence · Significant, low-quality evidence · Not stated in the abstract 50 mg/day for 4 weeks in a randomized double-blind placebo-controlled crossover trial in Parkinson's disease depression; significant HDRS improvement, no effect on apathy, and the authors call it preliminary. A single small trial in one population, cited by our 5-HTP with SSRIs guide. PMID 32067288 Obesity trial (900 mg/day) 900 mg · over two consecutive 6-wk periods · daily · n=20 · limited evidence · Significant, low-quality evidence · Not stated in the abstract 900 mg/day in 20 obese adults randomly assigned to 5-HTP or placebo, across two consecutive double-blind 6-week periods. No diet was prescribed during the first period. A 5040-kJ/d diet was recommended for the second. Significant weight loss, lower carbohydrate intake, and earlier satiety were seen on 5-HTP during both periods. The authors report good tolerance. PMID 1384305 Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain No floor is tagged as missed, secondary-only, or untagged.
Ashwagandha
Supplement Brief fact box · CC BY 4.0
| Benefit | Stress and cortisol RCT (Chandrasekhar 2012)
High-concentration full-spectrum root extract, 300 mg per day for eight weeks in a randomized double-blind placebo-controlled trial of 64 adults. Serum cortisol fell significantly versus placebo and a stress scale improved. The reference point for label comparison. Dose-ranging trial (Salve 2019)
Three-arm trial comparing 250 and 600 mg per day of root extract. Perceived stress improved on both doses and cortisol on both, with the stronger signal at 600 mg. Establishes the studied range rather than one number. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | No floor is tagged as missed, secondary-only, or untagged. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Ashwagandha Dose page: https://supplementbrief.com/dose/ashwagandha/ Safety: https://supplementbrief.com/dose/ashwagandha/#dose-red-flags-heading Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit Stress and cortisol RCT (Chandrasekhar 2012) 300 mg · over 8 weeks · daily · n=64 · medium evidence · Benefit shown · Industry (Ixoreal Biomedication (KSM-66 maker)) High-concentration full-spectrum root extract, 300 mg per day for eight weeks in a randomized double-blind placebo-controlled trial of 64 adults. Serum cortisol fell significantly versus placebo and a stress scale improved. The reference point for label comparison. PMID 23439798 Dose-ranging trial (Salve 2019) 250–600 mg · over 8 weeks · daily · limited evidence · Benefit shown · Independent Three-arm trial comparing 250 and 600 mg per day of root extract. Perceived stress improved on both doses and cortisol on both, with the stronger signal at 600 mg. Establishes the studied range rather than one number. PMID 32021735 Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain No floor is tagged as missed, secondary-only, or untagged.
| Benefit | No floor in this file is tagged as a benefit. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | Adiposity RCT (Lei 2026, MASLD)
Diabetes-free adults with obesity and MASLD. 1 g/day berberine vs placebo for 6 months. Pre-specified primary endpoints (visceral adipose tissue, liver fat) did not differ from placebo. Excellent safety profile. Not GLP-1-level adiposity reduction. Weight meta-analyses (1 g/day and up)
Pooled body-weight estimates unstable across meta-analyses (−0.11 kg to −2.07 kg). Dose-response suggests ≥1 g/day. Indirect evidence; not mirtazapine-specific. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Berberine Dose page: https://supplementbrief.com/dose/berberine/ Safety: https://supplementbrief.com/dose/berberine/#dose-red-flags-heading Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit No floor in this file is tagged as a benefit. Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain Adiposity RCT (Lei 2026, MASLD) 1,000 mg · over 6 months · daily · n=337 · medium evidence · Primary endpoint missed · Independent Diabetes-free adults with obesity and MASLD. 1 g/day berberine vs placebo for 6 months. Pre-specified primary endpoints (visceral adipose tissue, liver fat) did not differ from placebo. Excellent safety profile. Not GLP-1-level adiposity reduction. PMID 41543854 Weight meta-analyses (1 g/day and up) 1,000 mg · over 8-12 weeks · daily · medium evidence · Secondary outcomes only · Independent Pooled body-weight estimates unstable across meta-analyses (−0.11 kg to −2.07 kg). Dose-response suggests ≥1 g/day. Indirect evidence; not mirtazapine-specific. PMID 32379652, PMID 32690176
Chromium picolinate
Supplement Brief fact box · CC BY 4.0
| Benefit | No floor in this file is tagged as a benefit. |
|---|---|
| Weak benefit | Cochrane weight review (pooled doses)
Nine RCTs, 200–1000 µg/day chromium picolinate, 8–24 weeks. Body weight MD −1.1 kg (95% CI −1.7 to −0.4). Low-quality GRADE; debatable clinical relevance; no dose gradient. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | Pittler 2003 sensitivity analysis
Removing one influential trial: −0.9 kg (95% CI −2.0 to 0.2), not statistically significant. Funnel plot asymmetry suggests publication bias. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Chromium picolinate Dose page: https://supplementbrief.com/dose/chromium-picolinate/ Safety: https://supplementbrief.com/dose/chromium-picolinate/#dose-red-flags-heading Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit No floor in this file is tagged as a benefit. Weak benefit Cochrane weight review (pooled doses) 1,000 mcg · over 12-16 weeks · daily · n=622 · limited evidence · Significant, low-quality evidence · Independent Nine RCTs, 200–1000 µg/day chromium picolinate, 8–24 weeks. Body weight MD −1.1 kg (95% CI −1.7 to −0.4). Low-quality GRADE; debatable clinical relevance; no dose gradient. PMID 24293292 Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain Pittler 2003 sensitivity analysis 1,000 mcg · over 12-16 weeks · daily · limited evidence · Primary endpoint missed · Independent Removing one influential trial: −0.9 kg (95% CI −2.0 to 0.2), not statistically significant. Funnel plot asymmetry suggests publication bias. PMID 12664086
Collagen peptides (hydrolyzed)
Supplement Brief fact box · CC BY 4.0
| Benefit | Verisol skin trials (branded peptide)
Specific bioactive peptide preparation — generic 20 g powder is not equivalent evidence. Generic hydrolyzed collagen (instrumental skin trials)
Pooled human skin trials often land in 2.5–10 g/day depending on preparation and endpoint. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | No floor is tagged as missed, secondary-only, or untagged. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Collagen peptides (hydrolyzed) Dose page: https://supplementbrief.com/dose/collagen-peptides/ Safety: https://supplementbrief.com/dose/collagen-peptides/ Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit Verisol skin trials (branded peptide) 2.5 g · over 8 weeks · daily · medium evidence · Benefit shown · Not stated in the abstract Specific bioactive peptide preparation — generic 20 g powder is not equivalent evidence. PMID 24401291, PMID 23949208 Generic hydrolyzed collagen (instrumental skin trials) 2.5–10 g · daily · limited evidence · Benefit shown · Not stated in the abstract Pooled human skin trials often land in 2.5–10 g/day depending on preparation and endpoint. Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain No floor is tagged as missed, secondary-only, or untagged.
Creatine monohydrate
Supplement Brief fact box · CC BY 4.0
| Benefit | Maintenance (postmenopausal + training meta-analyses)
Seven-RCT meta-analysis in postmenopausal women found +0.37 kg lean mass (95% CI +0.05 to +0.69). Most included trials used ≥5 g/day with resistance training; 3 g/day is a common maintenance floor. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | Two-year bone trial dose (research)
~8–10 g at 60 kg. The primary endpoint failed — no effect on femoral neck, total hip or lumbar spine bone density over two years. Only secondary femoral-neck geometry (section modulus, buckling ratio) favoured creatine. This is a dose reference, not evidence that creatine builds bone. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Creatine monohydrate Dose page: https://supplementbrief.com/dose/creatine/ Safety: https://supplementbrief.com/dose/creatine/ Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit Maintenance (postmenopausal + training meta-analyses) 3–5 g · daily · n=608 · medium evidence · Benefit shown · Mixed (Alzchem (APC support)) Seven-RCT meta-analysis in postmenopausal women found +0.37 kg lean mass (95% CI +0.05 to +0.69). Most included trials used ≥5 g/day with resistance training; 3 g/day is a common maintenance floor. PMID 42141930 Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain Two-year bone trial dose (research) 0.14 g/kg · over 2 years · daily · n=237 · limited evidence · Primary endpoint missed · Not stated in the abstract ~8–10 g at 60 kg. The primary endpoint failed — no effect on femoral neck, total hip or lumbar spine bone density over two years. Only secondary femoral-neck geometry (section modulus, buckling ratio) favoured creatine. This is a dose reference, not evidence that creatine builds bone. PMID 37144634
Dietary protein (complete)
Supplement Brief fact box · CC BY 4.0
| Benefit | GLP-1 / weight-loss lean-mass context
Multiply body weight (kg) by 1.2–1.6 for grams per day — not a fixed gram dose. Use the protein target calculator. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | Example at 70 kg (1.2–1.6 g/kg)
Illustrative only — enter your weight in the protein calculator. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Dietary protein (complete) Dose page: https://supplementbrief.com/dose/protein/ Safety: https://supplementbrief.com/dose/protein/ Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit GLP-1 / weight-loss lean-mass context 1.2–1.6 g/kg · daily · medium evidence · Benefit shown · Not stated in the abstract Multiply body weight (kg) by 1.2–1.6 for grams per day — not a fixed gram dose. Use the protein target calculator. PMID 42560932 Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain Example at 70 kg (1.2–1.6 g/kg) 84–112 g · daily · medium evidence · Not stated in the abstract Illustrative only — enter your weight in the protein calculator.
Garlic (aged extract)
Supplement Brief fact box · CC BY 4.0
| Benefit | No floor in this file is tagged as a benefit. |
|---|---|
| Weak benefit | Aged garlic extract RCT (Ried 2018)
1.2 g per day of Kyolic aged garlic extract, standardized to S-allylcysteine, for three months in adults with hypertension (the GarGIC trial). Moved blood pressure, arterial stiffness, and inflammation-related markers in a modest, part-of-the-population way; earlier AGE trials showed clearer blood-pressure effects in hypertensive subgroups. Honest read: a real but modest cardiovascular-risk candidate, in one studied form. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | No floor is tagged as missed, secondary-only, or untagged. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Garlic (aged extract) Dose page: https://supplementbrief.com/dose/garlic/ Safety: https://supplementbrief.com/dose/garlic/#dose-red-flags-heading Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit No floor in this file is tagged as a benefit. Weak benefit Aged garlic extract RCT (Ried 2018) 1.2 g · over 3 months · daily · limited evidence · Significant, low-quality evidence · Not stated in the abstract 1.2 g per day of Kyolic aged garlic extract, standardized to S-allylcysteine, for three months in adults with hypertension (the GarGIC trial). Moved blood pressure, arterial stiffness, and inflammation-related markers in a modest, part-of-the-population way; earlier AGE trials showed clearer blood-pressure effects in hypertensive subgroups. Honest read: a real but modest cardiovascular-risk candidate, in one studied form. PMID 30619868 Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain No floor is tagged as missed, secondary-only, or untagged.
Ginkgo biloba (EGb 761)
Supplement Brief fact box · CC BY 4.0
| Benefit | No floor in this file is tagged as a benefit. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | Standardized EGb 761 extract (Kang 2002)
120-240 mg per day of standardized EGb 761 (24% ginkgo flavone glycosides) is the extract standard nearly the whole evidence base was built on. Kang 2002, a small early RCT in 37 adults on fluoxetine or paroxetine, was positive; three later RCTs were null, which is why the effect direction here reads null. This floor is about the extract and dose standard, not a promise of effect. 900 mg open-label pilots (historical only)
Ashton 2000 and Cohen 1998, open-label pilots at 900 mg per day. Kept as historical context only: we do not present 900 mg as a target, and the controlled trials at the standard dose did not replicate the pilots. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Ginkgo biloba (EGb 761) Dose page: https://supplementbrief.com/dose/ginkgo-biloba/ Safety: https://supplementbrief.com/dose/ginkgo-biloba/#dose-red-flags-heading Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit No floor in this file is tagged as a benefit. Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain Standardized EGb 761 extract (Kang 2002) 120–240 mg · over 8+ weeks · daily · n=37 · limited evidence · Primary endpoint missed · Not stated in the abstract 120-240 mg per day of standardized EGb 761 (24% ginkgo flavone glycosides) is the extract standard nearly the whole evidence base was built on. Kang 2002, a small early RCT in 37 adults on fluoxetine or paroxetine, was positive; three later RCTs were null, which is why the effect direction here reads null. This floor is about the extract and dose standard, not a promise of effect. PMID 12404672 900 mg open-label pilots (historical only) 900 mg · over 4-8 weeks · daily · limited evidence · Primary endpoint missed · Not stated in the abstract Ashton 2000 and Cohen 1998, open-label pilots at 900 mg per day. Kept as historical context only: we do not present 900 mg as a target, and the controlled trials at the standard dose did not replicate the pilots. PMID 10784488, PMID 9611693
Glucomannan (konjac)
Supplement Brief fact box · CC BY 4.0
| Benefit | No floor in this file is tagged as a benefit. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | Typical trial dose (anchor, not meta mean)
Zahra 2020 meta-analysis, six RCTs pooled −0.96 kg (95% CI −1.81 to −0.11), I²=88% (Obesity Medicine 2020;9:100276, doi:10.1016/j.obmed.2020.100276; journal is not PubMed-indexed, no PMID). Meta did not report pooled mean dose; 3 g/day before meals, split into 1 g doses three times daily, is typical in constituent trials and the EFSA minimum for the weight claim. Psyllium 10.8 g/day is the stronger fiber anchor in this guide. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Glucomannan (konjac) Dose page: https://supplementbrief.com/dose/glucomannan/ Safety: https://supplementbrief.com/dose/glucomannan/#dose-red-flags-heading Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit No floor in this file is tagged as a benefit. Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain Typical trial dose (anchor, not meta mean) 3 g · over 8-12 weeks · daily · n=225 · limited evidence · Secondary outcomes only · Not stated in the abstract Zahra 2020 meta-analysis, six RCTs pooled −0.96 kg (95% CI −1.81 to −0.11), I²=88% (Obesity Medicine 2020;9:100276, doi:10.1016/j.obmed.2020.100276; journal is not PubMed-indexed, no PMID). Meta did not report pooled mean dose; 3 g/day before meals, split into 1 g doses three times daily, is typical in constituent trials and the EFSA minimum for the weight claim. Psyllium 10.8 g/day is the stronger fiber anchor in this guide.
Green tea extract (EGCG)
Supplement Brief fact box · CC BY 4.0
| Benefit | No floor in this file is tagged as a benefit. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | Cochrane weight-loss review
15 weight-loss trials. Small, statistically non-significant pooled effect; authors concluded not clinically important. Outside Japan MD −0.04 kg (95% CI −0.5 to 0.4). Dose-response meta (Lin 2020)
Pooled −1.78 kg (95% CI −2.80 to −0.75). Waist reduction greater at ≥800 mg/day green tea preparations and duration <12 weeks. Heterogeneous extract types; part of effect is caffeine. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Green tea extract (EGCG) Dose page: https://supplementbrief.com/dose/green-tea-egcg/ Safety: https://supplementbrief.com/dose/green-tea-egcg/#dose-red-flags-heading Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit No floor in this file is tagged as a benefit. Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain Cochrane weight-loss review 800 mg · over 12-13 weeks · daily · n=1,945 · medium evidence · Primary endpoint missed · Independent 15 weight-loss trials. Small, statistically non-significant pooled effect; authors concluded not clinically important. Outside Japan MD −0.04 kg (95% CI −0.5 to 0.4). PMID 23235664 Dose-response meta (Lin 2020) 800 mg · over 8-12 weeks · daily · medium evidence · Secondary outcomes only · Independent Pooled −1.78 kg (95% CI −2.80 to −0.75). Waist reduction greater at ≥800 mg/day green tea preparations and duration <12 weeks. Heterogeneous extract types; part of effect is caffeine. PMID 32372444
Korean red ginseng (Panax ginseng)
Supplement Brief fact box · CC BY 4.0
| Benefit | 1000 mg three times daily (de Andrade 2007)
IIEF-5 rose from 16.4 to 21.0 against no change on placebo, and 66.6% reported improved erection. Testosterone, prolactin and cholesterol were unchanged, so this is not a hormonal mechanism. Single centre, mild to mild-moderate ED only. 900 mg three times daily (Hong 2002)
Double-blind crossover with an 8-week washout design. IIEF total and RigiScan penile tip rigidity both improved; 60% reported better erections. Explicitly published as a preliminary report. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | Cochrane pooled estimate (effect rated trivial)
Nine RCTs, 587 men. Pooled IIEF-15 erectile-function difference was 3.52 points against a minimal clinically important difference of 4, and IIEF-5 was 2.39 points — Cochrane called the effect trivial at low-to-moderate certainty. The dose is real; the benefit at that dose is small on average. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Korean red ginseng (Panax ginseng) Dose page: https://supplementbrief.com/dose/panax-ginseng/ Safety: https://supplementbrief.com/dose/panax-ginseng/#dose-red-flags-heading Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit 1000 mg three times daily (de Andrade 2007) 3 g · over 12 weeks · daily · n=60 · limited evidence · Benefit shown · Independent IIEF-5 rose from 16.4 to 21.0 against no change on placebo, and 66.6% reported improved erection. Testosterone, prolactin and cholesterol were unchanged, so this is not a hormonal mechanism. Single centre, mild to mild-moderate ED only. PMID 16855773 900 mg three times daily (Hong 2002) 2.7 g · over 8 weeks · daily · n=45 · limited evidence · Benefit shown · Independent Double-blind crossover with an 8-week washout design. IIEF total and RigiScan penile tip rigidity both improved; 60% reported better erections. Explicitly published as a preliminary report. PMID 12394711 Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain Cochrane pooled estimate (effect rated trivial) 3 g · daily · n=587 · medium evidence · Primary endpoint missed · Independent Nine RCTs, 587 men. Pooled IIEF-15 erectile-function difference was 3.52 points against a minimal clinically important difference of 4, and IIEF-5 was 2.39 points — Cochrane called the effect trivial at low-to-moderate certainty. The dose is real; the benefit at that dose is small on average. PMID 33871063
L-arginine
Supplement Brief fact box · CC BY 4.0
| Benefit | Menafra 2022 (vasculogenic ED)
Multicentre double-blind RCT (51 arginine / 47 placebo) in vasculogenic ED. IIEF-6 and cavernous peak systolic velocity both improved, but only 24% reached scores compatible with no ED — mostly the mild-ED subgroup. High daily gram burden vs citrulline trials. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | No floor is tagged as missed, secondary-only, or untagged. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
L-arginine Dose page: https://supplementbrief.com/dose/l-arginine/ Safety: https://supplementbrief.com/dose/l-arginine/#dose-red-flags-heading Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit Menafra 2022 (vasculogenic ED) 6 g · over 3 months · daily · n=98 · medium evidence · Benefit shown · Independent Multicentre double-blind RCT (51 arginine / 47 placebo) in vasculogenic ED. IIEF-6 and cavernous peak systolic velocity both improved, but only 24% reached scores compatible with no ED — mostly the mild-ED subgroup. High daily gram burden vs citrulline trials. PMID 34973154 Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain No floor is tagged as missed, secondary-only, or untagged.
L-citrulline
Supplement Brief fact box · CC BY 4.0
| Benefit | Cormio 2011 pilot (mild ED)
Single-blind pilot; 95% CI not reported in primary paper. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | No floor is tagged as missed, secondary-only, or untagged. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
L-citrulline Dose page: https://supplementbrief.com/dose/l-citrulline/ Safety: https://supplementbrief.com/dose/l-citrulline/#dose-red-flags-heading Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit Cormio 2011 pilot (mild ED) 1.5 g · over 1 month · daily · n=24 · limited evidence · Benefit shown · Independent Single-blind pilot; 95% CI not reported in primary paper. PMID 21195829 Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain No floor is tagged as missed, secondary-only, or untagged.
Maca root (Lepidium meyenii)
Supplement Brief fact box · CC BY 4.0
| Benefit | Antidepressant-induced sexual dysfunction, women
Placebo-controlled, 45 women on SSRIs or SNRIs randomised. Remission favoured maca but stayed low in absolute terms — 9.5% vs 4.8% by ASEX and 30% vs 20% by MGH-SFQ — and the benefit clustered in postmenopausal women. Women only; there is no male equivalent of this trial. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | Dose-finding pilot, 1.5 g arm failed
Head-to-head 1.5 g/day vs 3.0 g/day in 20 remitted depressed outpatients, 17 of them women. Only the 3.0 g arm improved significantly on ASEX and MGH-SFQ; 1.5 g/day did not separate. Ten completers. This is the entry's evidence that the lower dose is below the floor, not above it. Men with mild ED, subjective wellbeing
The only randomised maca trial in men, and it was mild general ED rather than antidepressant-induced. Both arms improved; maca improved more, but IIEF-5 gained only 1.6 points vs 0.5 on placebo — far below the roughly 4-point threshold for a change men notice. The paper frames its own outcome as subjective wellbeing. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Maca root (Lepidium meyenii) Dose page: https://supplementbrief.com/dose/maca/ Safety: https://supplementbrief.com/dose/maca/ Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit Antidepressant-induced sexual dysfunction, women 3 g · over 12 weeks · daily · n=42 · limited evidence · Benefit shown · Not stated in the abstract Placebo-controlled, 45 women on SSRIs or SNRIs randomised. Remission favoured maca but stayed low in absolute terms — 9.5% vs 4.8% by ASEX and 30% vs 20% by MGH-SFQ — and the benefit clustered in postmenopausal women. Women only; there is no male equivalent of this trial. PMID 25954318 Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain Dose-finding pilot, 1.5 g arm failed 1.5–3 g · daily · n=16 · limited evidence · Primary endpoint missed · Not stated in the abstract Head-to-head 1.5 g/day vs 3.0 g/day in 20 remitted depressed outpatients, 17 of them women. Only the 3.0 g arm improved significantly on ASEX and MGH-SFQ; 1.5 g/day did not separate. Ten completers. This is the entry's evidence that the lower dose is below the floor, not above it. PMID 18801111 Men with mild ED, subjective wellbeing 2.4 g · over 12 weeks · daily · n=50 · limited evidence · Secondary outcomes only · Not stated in the abstract The only randomised maca trial in men, and it was mild general ED rather than antidepressant-induced. Both arms improved; maca improved more, but IIEF-5 gained only 1.6 points vs 0.5 on placebo — far below the roughly 4-point threshold for a change men notice. The paper frames its own outcome as subjective wellbeing. PMID 19260845
Magnesium (elemental)
Supplement Brief fact box · CC BY 4.0
| Benefit | Form-comparison trial (elemental)
300 mg elemental per day compared citrate, amino-acid chelate and oxide in healthy adults. The endpoint was absorption (urinary, serum, salivary magnesium), not a symptom — oxide did not separate from placebo. Bisglycinate sleep trial (elemental)
250 mg elemental as bisglycinate beat placebo on Insomnia Severity Index at week 4, but the effect was small (Cohen's d = 0.2) and concentrated in people with low dietary magnesium intake. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | Daily value (women)
FDA daily value reference — not a trial dose. Daily value (men)
FDA daily value reference — not a trial dose. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Magnesium (elemental) Dose page: https://supplementbrief.com/dose/magnesium/ Safety: https://supplementbrief.com/dose/magnesium/#dose-red-flags-heading Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit Form-comparison trial (elemental) 300 mg · over 60 days · daily · n=46 · medium evidence · Benefit shown · Not stated in the abstract 300 mg elemental per day compared citrate, amino-acid chelate and oxide in healthy adults. The endpoint was absorption (urinary, serum, salivary magnesium), not a symptom — oxide did not separate from placebo. PMID 14596323 Bisglycinate sleep trial (elemental) 250 mg · over 4 weeks · daily · n=155 · limited evidence · Benefit shown · Industry (Lopresti (nutraceutical funding)) 250 mg elemental as bisglycinate beat placebo on Insomnia Severity Index at week 4, but the effect was small (Cohen's d = 0.2) and concentrated in people with low dietary magnesium intake. PMID 40918053 Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain Daily value (women) 320 mg · daily · high evidence · Not stated in the abstract FDA daily value reference — not a trial dose. Daily value (men) 420 mg · daily · high evidence · Not stated in the abstract FDA daily value reference — not a trial dose.
Magnesium L-threonate
Supplement Brief fact box · CC BY 4.0
| Benefit | No floor in this file is tagged as a benefit. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | Cognition and sleep trial (compound weight)
2 g/day of branded Magtein in adults aged 18-45 reporting unsatisfying sleep. Overall cognition improved (NIH Total Cognition Composite, p = 0.043) along with reaction time, resting heart rate and HRV. Raven's matrices did not change, and neither did objective sleep from a wearable — only self-reported sleep-related impairment. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Magnesium L-threonate Dose page: https://supplementbrief.com/dose/magnesium-l-threonate/ Safety: https://supplementbrief.com/dose/magnesium-l-threonate/ Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit No floor in this file is tagged as a benefit. Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain Cognition and sleep trial (compound weight) 2,000 mg · over 6 weeks · daily · n=100 · limited evidence · Secondary outcomes only · Industry (Threotech Inc.) 2 g/day of branded Magtein in adults aged 18-45 reporting unsatisfying sleep. Overall cognition improved (NIH Total Cognition Composite, p = 0.043) along with reaction time, resting heart rate and HRV. Raven's matrices did not change, and neither did objective sleep from a wearable — only self-reported sleep-related impairment. PMID 41601871
| Benefit | Delayed sleep-wake phase disorder, 0.5 mg timed
0.5 mg fast-release taken one hour before the desired bedtime, alongside behavioural sleep-wake scheduling in both arms. Sleep onset moved 34 minutes earlier (95% CI −60 to −8) and 52.8% improved on clinician rating vs 24.0% on placebo. The scheduling was part of the treatment — this is not a melatonin-alone result. Circadian phase advance, timing over dose
0.3 mg and 3.0 mg advanced circadian phase by the same amount. What predicted the size of the shift was when the dose was taken relative to dim-light melatonin onset (r² = 0.94), not how much was taken. Thirteen subjects. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | No floor is tagged as missed, secondary-only, or untagged. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Melatonin Dose page: https://supplementbrief.com/dose/melatonin/ Safety: https://supplementbrief.com/dose/melatonin/ Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit Delayed sleep-wake phase disorder, 0.5 mg timed 0.5 mg · over 4 weeks · daily · n=116 · medium evidence · Benefit shown · Not stated in the abstract 0.5 mg fast-release taken one hour before the desired bedtime, alongside behavioural sleep-wake scheduling in both arms. Sleep onset moved 34 minutes earlier (95% CI −60 to −8) and 52.8% improved on clinician rating vs 24.0% on placebo. The scheduling was part of the treatment — this is not a melatonin-alone result. PMID 29912983 Circadian phase advance, timing over dose 0.3–3 mg · over 4 weeks · daily · n=13 · limited evidence · Benefit shown · Not stated in the abstract 0.3 mg and 3.0 mg advanced circadian phase by the same amount. What predicted the size of the shift was when the dose was taken relative to dim-light melatonin onset (r² = 0.94), not how much was taken. Thirteen subjects. PMID 16295212 Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain No floor is tagged as missed, secondary-only, or untagged.
Nicotinamide riboside
Supplement Brief fact box · CC BY 4.0
| Benefit | No floor in this file is tagged as a benefit. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | NAD+ elevation trial (1000 mg/day)
1000 mg/day for 6 weeks in a randomized double-blind crossover trial in healthy middle-aged and older adults; well-tolerated, elevated whole-blood NAD+. Cited in our urolithin A vs NMN guide, which covers the NAD+ booster shelf context. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Nicotinamide riboside Dose page: https://supplementbrief.com/dose/nicotinamide-riboside/ Safety: https://supplementbrief.com/dose/nicotinamide-riboside/ Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit No floor in this file is tagged as a benefit. Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain NAD+ elevation trial (1000 mg/day) 1,000 mg · over 6 weeks · daily · n=24 · limited evidence · Secondary outcomes only · Independent 1000 mg/day for 6 weeks in a randomized double-blind crossover trial in healthy middle-aged and older adults; well-tolerated, elevated whole-blood NAD+. Cited in our urolithin A vs NMN guide, which covers the NAD+ booster shelf context. PMID 29599478
Omega-3 (EPA + DHA combined)
Supplement Brief fact box · CC BY 4.0
| Benefit | OTC inflammatory-marker meta-analyses (EPA+DHA)
Active dose is EPA + DHA on the Supplement Facts panel — not total fish oil weight. This range is the span of doses pooled across 68 RCTs and 32 meta-analyses; neither review identifies a single threshold dose, and the CRP effect weakened above BMI 30. REDUCE-IT (prescription icosapent ethyl)
Prescription purified EPA — not comparable to a standard fish oil capsule. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | EPA dose-finding in inflammatory depression
EPA-only, in adults with major depression plus BMI over 25 and hs-CRP at or above 3 mg/L. Response was 64% vs 40% on placebo (Cohen d = 0.53) but not statistically significant, and the prespecified IL-6 and TNF endpoints were missed. A dose-finding signal in a narrow phenotype, not an established dose. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Omega-3 (EPA + DHA combined) Dose page: https://supplementbrief.com/dose/omega-3/ Safety: https://supplementbrief.com/dose/omega-3/#dose-red-flags-heading Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit OTC inflammatory-marker meta-analyses (EPA+DHA) 1–2 g · daily · medium evidence · Benefit shown · Independent Active dose is EPA + DHA on the Supplement Facts panel — not total fish oil weight. This range is the span of doses pooled across 68 RCTs and 32 meta-analyses; neither review identifies a single threshold dose, and the CRP effect weakened above BMI 30. PMID 24505395, PMID 35914448 REDUCE-IT (prescription icosapent ethyl) 4 g · daily · high evidence · Benefit shown · Industry (Amarin Pharma) Prescription purified EPA — not comparable to a standard fish oil capsule. PMID 30415628 Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain EPA dose-finding in inflammatory depression 4 g · over 12 weeks · daily · n=45 · limited evidence · Primary endpoint missed · Not stated in the abstract EPA-only, in adults with major depression plus BMI over 25 and hs-CRP at or above 3 mg/L. Response was 64% vs 40% on placebo (Cohen d = 0.53) but not statistically significant, and the prespecified IL-6 and TNF endpoints were missed. A dose-finding signal in a narrow phenotype, not an established dose. PMID 36005883
| Benefit | No floor in this file is tagged as a benefit. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | US OTC pill limit (FDA)
The 99 mg elemental potassium limit per over-the-counter pill in the US exists because higher single-pill doses can injure the gut lining and because a bottle of high-dose pills is a hyperkalemia hazard in the wrong kidney. This entry is a ceiling, not a trial floor: potassium has no studied supplement dose, because its risk profile runs the other way. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Potassium Dose page: https://supplementbrief.com/dose/potassium/ Safety: https://supplementbrief.com/dose/potassium/#dose-red-flags-heading Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit No floor in this file is tagged as a benefit. Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain US OTC pill limit (FDA) 99 mg · over ongoing · daily · high evidence · Not stated in the abstract The 99 mg elemental potassium limit per over-the-counter pill in the US exists because higher single-pill doses can injure the gut lining and because a bottle of high-dose pills is a hyperkalemia hazard in the wrong kidney. This entry is a ceiling, not a trial floor: potassium has no studied supplement dose, because its risk profile runs the other way.
Psyllium husk fibre
Supplement Brief fact box · CC BY 4.0
| Benefit | Chronic constipation meta-analysis (response threshold)
Sixteen RCTs in 1,251 chronically constipated adults. Symptom response was 66 percent on fibre versus 41 percent on control, and the subgroup analysis localized the effect to psyllium and pectin; stool frequency improved only above 10 g/day and only past four weeks. The classic dose-ranging study found 20 to 30 g/day beat 10 g on symptoms with dose-dependent stool weight gain, so titrate up from a teaspoon per dose instead of starting high. Weight-loss meta-analysis (mean dose, before meals)
Six RCTs in overweight and obese adults. Body weight fell 2.1 kg (95% CI −2.6 to −1.6), BMI 0.8 kg/m² and waist circumference 2.2 cm. 10.8 g/day is the mean dose across those trials, taken just before meals over a mean 4.8 months — the timing is part of the protocol, not a detail. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | No floor is tagged as missed, secondary-only, or untagged. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Psyllium husk fibre Dose page: https://supplementbrief.com/dose/psyllium/ Safety: https://supplementbrief.com/dose/psyllium/#dose-red-flags-heading Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit Chronic constipation meta-analysis (response threshold) 10–30 g · over 4+ weeks · daily · n=1,251 · medium evidence · Benefit shown · Not stated in the abstract Sixteen RCTs in 1,251 chronically constipated adults. Symptom response was 66 percent on fibre versus 41 percent on control, and the subgroup analysis localized the effect to psyllium and pectin; stool frequency improved only above 10 g/day and only past four weeks. The classic dose-ranging study found 20 to 30 g/day beat 10 g on symptoms with dose-dependent stool weight gain, so titrate up from a teaspoon per dose instead of starting high. PMID 35816465, PMID 3030900 Weight-loss meta-analysis (mean dose, before meals) 11 g · over 4-5 months · daily · n=354 · medium evidence · Benefit shown · Industry (employees of a commercial entity) Six RCTs in overweight and obese adults. Body weight fell 2.1 kg (95% CI −2.6 to −1.6), BMI 0.8 kg/m² and waist circumference 2.2 cm. 10.8 g/day is the mean dose across those trials, taken just before meals over a mean 4.8 months — the timing is part of the protocol, not a detail. PMID 37163454 Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain No floor is tagged as missed, secondary-only, or untagged.
Red yeast rice
Supplement Brief fact box · CC BY 4.0
| Benefit | Statin-intolerant RCT (Becker 2009)
1,800 mg twice per day (3,600 mg per day total) for 24 weeks in 62 adults with statin-intolerant dyslipidemia, randomized against placebo. LDL fell significantly. The effect is real because the active molecule is real: monacolin K is chemically identical to lovastatin, a statin-class drug effect delivered through a supplement label. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | No floor is tagged as missed, secondary-only, or untagged. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Red yeast rice Dose page: https://supplementbrief.com/dose/red-yeast-rice/ Safety: https://supplementbrief.com/dose/red-yeast-rice/#dose-red-flags-heading Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit Statin-intolerant RCT (Becker 2009) 3,600 mg · over 24 weeks · daily · n=62 · limited evidence · Benefit shown · Independent 1,800 mg twice per day (3,600 mg per day total) for 24 weeks in 62 adults with statin-intolerant dyslipidemia, randomized against placebo. LDL fell significantly. The effect is real because the active molecule is real: monacolin K is chemically identical to lovastatin, a statin-class drug effect delivered through a supplement label. PMID 19528562 Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain No floor is tagged as missed, secondary-only, or untagged.
Saffron (Crocus sativus) extract
Supplement Brief fact box · CC BY 4.0
| Benefit | Fluoxetine-related sexual dysfunction, men
15 mg twice daily in men whose depression was already stabilised on fluoxetine. Erectile function and intercourse satisfaction improved; orgasmic function, overall satisfaction and desire did not. Thirty completers in a single Iranian centre. Fluoxetine-related sexual dysfunction, women
Same 30 mg/day in women stabilised on fluoxetine 40 mg. Total FSFI, arousal, lubrication and pain improved; desire did not. Separate trial, separate instrument — do not read the men's result into this one or the reverse. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | Postpartum depression, saffron vs fluoxetine
15 mg twice daily against fluoxetine 20 mg twice daily in mild-to-moderate postpartum depression. There was no significant difference between arms, and complete response was 40.6% on saffron vs 50.0% on fluoxetine — an active-comparator trial with no placebo arm, so it does not establish that saffron beat nothing. Depression meta-analyses (pooled)
Pooled saffron-vs-placebo effect was large but the confidence interval reached zero (SMD −0.86, 95% CI −1.73 to 0.00), and saffron did not differ from fluoxetine. Eight small trials, most from a single country. Treat 30 mg/day as the dose those trials used, not as a settled effective dose. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Saffron (Crocus sativus) extract Dose page: https://supplementbrief.com/dose/saffron/ Safety: https://supplementbrief.com/dose/saffron/ Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit Fluoxetine-related sexual dysfunction, men 30 mg · over 4 weeks · daily · n=30 · limited evidence · Benefit shown · Not stated in the abstract 15 mg twice daily in men whose depression was already stabilised on fluoxetine. Erectile function and intercourse satisfaction improved; orgasmic function, overall satisfaction and desire did not. Thirty completers in a single Iranian centre. PMID 22552758 Fluoxetine-related sexual dysfunction, women 30 mg · over 4 weeks · daily · n=34 · limited evidence · Benefit shown · Not stated in the abstract Same 30 mg/day in women stabilised on fluoxetine 40 mg. Total FSFI, arousal, lubrication and pain improved; desire did not. Separate trial, separate instrument — do not read the men's result into this one or the reverse. PMID 23280545 Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain Postpartum depression, saffron vs fluoxetine 30 mg · over 6 weeks · daily · n=64 · limited evidence · Primary endpoint missed · Not stated in the abstract 15 mg twice daily against fluoxetine 20 mg twice daily in mild-to-moderate postpartum depression. There was no significant difference between arms, and complete response was 40.6% on saffron vs 50.0% on fluoxetine — an active-comparator trial with no placebo arm, so it does not establish that saffron beat nothing. PMID 27595298 Depression meta-analyses (pooled) 30 mg · daily · limited evidence · Primary endpoint missed · Industry (Reserveage Organics) Pooled saffron-vs-placebo effect was large but the confidence interval reached zero (SMD −0.86, 95% CI −1.73 to 0.00), and saffron did not differ from fluoxetine. Eight small trials, most from a single country. Treat 30 mg/day as the dose those trials used, not as a settled effective dose. PMID 24299602, PMID 31118846
Urolithin A
Supplement Brief fact box · CC BY 4.0
| Benefit | No floor in this file is tagged as a benefit. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | ATLAS trial, branded Mitopure
Two doses of branded Mitopure in middle-aged adults for four months. The primary endpoint — peak power output — was not met. Muscle strength rose about 12%, with improvements in peak VO2, six-minute walk, plasma acylcarnitines and CRP as secondary outcomes. Manufacturer-run trial on a specific synthesised preparation. Older adults, 1000 mg
Adults 65-90. Both primary endpoints failed — six-minute walk distance and maximal ATP production in hand muscle were no better than placebo. Secondary muscle endurance in two muscles and plasma biomarkers did improve. Safe and well tolerated. Safety and mitochondrial gene signature
Sedentary older adults. This trial established tolerability and showed the compound reaches muscle and shifts mitochondrial gene expression. There was no strength or performance endpoint at all — it answers "does oral urolithin A do anything in tissue", not "will I be stronger". Endothelial function trial (1000 mg)
Double-blind placebo-controlled single-site trial in adults 40-64 with obesity; the primary endpoint, brachial artery flow-mediated dilation, did not separate from placebo, nor did secondary peripheral endothelial measures. Exploratory cerebrovascular hemodynamics moved in the urolithin group. Cited by our urolithin A vs NMN guide. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Urolithin A Dose page: https://supplementbrief.com/dose/urolithin-a/ Safety: https://supplementbrief.com/dose/urolithin-a/ Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit No floor in this file is tagged as a benefit. Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain ATLAS trial, branded Mitopure 500–1,000 mg · over 4 months · daily · limited evidence · Secondary outcomes only · Industry (Amprocell (ATLAS sponsor)) Two doses of branded Mitopure in middle-aged adults for four months. The primary endpoint — peak power output — was not met. Muscle strength rose about 12%, with improvements in peak VO2, six-minute walk, plasma acylcarnitines and CRP as secondary outcomes. Manufacturer-run trial on a specific synthesised preparation. PMID 35584623 Older adults, 1000 mg 1,000 mg · over 4 months · daily · n=66 · limited evidence · Primary endpoint missed · Not stated in the abstract Adults 65-90. Both primary endpoints failed — six-minute walk distance and maximal ATP production in hand muscle were no better than placebo. Secondary muscle endurance in two muscles and plasma biomarkers did improve. Safe and well tolerated. PMID 35050355 Safety and mitochondrial gene signature 500–1,000 mg · over 4 weeks · daily · n=60 · limited evidence · Primary endpoint missed · Not stated in the abstract Sedentary older adults. This trial established tolerability and showed the compound reaches muscle and shifts mitochondrial gene expression. There was no strength or performance endpoint at all — it answers "does oral urolithin A do anything in tissue", not "will I be stronger". PMID 32694802 Endothelial function trial (1000 mg) 1,000 mg · over 4 weeks · daily · n=50 · limited evidence · Primary endpoint missed · Independent Double-blind placebo-controlled single-site trial in adults 40-64 with obesity; the primary endpoint, brachial artery flow-mediated dilation, did not separate from placebo, nor did secondary peripheral endothelial measures. Exploratory cerebrovascular hemodynamics moved in the urolithin group. Cited by our urolithin A vs NMN guide. PMID 42853569
Vitamin B12 (cobalamin)
Supplement Brief fact box · CC BY 4.0
| Benefit | Oral repletion (deficiency confirmed)
1000 mcg/day oral methylcobalamin for a year normalised B12 and improved nerve conduction in metformin-treated diabetic neuropathy; the Cochrane review found oral matches intramuscular for correcting levels. After labs, with clinician oversight. |
|---|---|
| Weak benefit | No floor in this file is tagged as a weak benefit. |
| Harm | No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page. |
| Uncertain | Typical multivitamin (not therapeutic)
Illustrative floor only — not sufficient for metformin-associated deficiency repletion. |
| A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. | |
Vitamin B12 (cobalamin) Dose page: https://supplementbrief.com/dose/vitamin-b12/ Safety: https://supplementbrief.com/dose/vitamin-b12/ Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/ A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe. Benefit Oral repletion (deficiency confirmed) 1,000 mcg · over 1 year · daily · n=90 · medium evidence · Benefit shown · Independent 1000 mcg/day oral methylcobalamin for a year normalised B12 and improved nerve conduction in metformin-treated diabetic neuropathy; the Cochrane review found oral matches intramuscular for correcting levels. After labs, with clinician oversight. PMID 33513879, PMID 29543316 Weak benefit No floor in this file is tagged as a weak benefit. Harm No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Uncertain Typical multivitamin (not therapeutic) 6–25 mcg · daily · high evidence · Not stated in the abstract Illustrative floor only — not sufficient for metformin-associated deficiency repletion.